A Double-blind, Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P, CBD) as Add-on Therapy in Patients With Tuberous Sclerosis Complex Who Experience Inadequately-controlled Seizures.

Trial Profile

A Double-blind, Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P, CBD) as Add-on Therapy in Patients With Tuberous Sclerosis Complex Who Experience Inadequately-controlled Seizures.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Seizures; Tuberous sclerosis
  • Focus Adverse reactions
  • Sponsors GW Pharmaceuticals
  • Most Recent Events

    • 04 Dec 2017 According to a GW Pharmaceuticals media release, data from this trial is expected in H2 2018.
    • 20 Oct 2017 Planned number of patients changed from 192 to 210.
    • 20 Oct 2017 Planned End Date changed from 1 Jul 2018 to 1 Sep 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top